AU733194B2 - Novel process for manufacturing paroxetine solid dispersions - Google Patents

Novel process for manufacturing paroxetine solid dispersions Download PDF

Info

Publication number
AU733194B2
AU733194B2 AU81717/98A AU8171798A AU733194B2 AU 733194 B2 AU733194 B2 AU 733194B2 AU 81717/98 A AU81717/98 A AU 81717/98A AU 8171798 A AU8171798 A AU 8171798A AU 733194 B2 AU733194 B2 AU 733194B2
Authority
AU
Australia
Prior art keywords
paroxetine
pharmaceutically acceptable
hydrogen chloride
polymeric carrier
free base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU81717/98A
Other languages
English (en)
Other versions
AU8171798A (en
Inventor
Sou-Chan Chang
William A. Ii Hein
Philip J. Krape
Christopher A. Teleha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endo Pharmaceuticals Inc
Original Assignee
Endo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Pharmaceuticals Inc filed Critical Endo Pharmaceuticals Inc
Publication of AU8171798A publication Critical patent/AU8171798A/en
Application granted granted Critical
Publication of AU733194B2 publication Critical patent/AU733194B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU81717/98A 1997-06-30 1998-06-26 Novel process for manufacturing paroxetine solid dispersions Ceased AU733194B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/885068 1997-06-30
US08/885,068 US5955475A (en) 1997-06-30 1997-06-30 Process for manufacturing paroxetine solid dispersions
PCT/US1998/013350 WO1999000131A1 (en) 1997-06-30 1998-06-26 Novel process for manufacturing paroxetine solid dispersions

Publications (2)

Publication Number Publication Date
AU8171798A AU8171798A (en) 1999-01-19
AU733194B2 true AU733194B2 (en) 2001-05-10

Family

ID=25386061

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81717/98A Ceased AU733194B2 (en) 1997-06-30 1998-06-26 Novel process for manufacturing paroxetine solid dispersions

Country Status (23)

Country Link
US (1) US5955475A (ko)
EP (1) EP0991408B1 (ko)
JP (1) JP2002514227A (ko)
KR (1) KR100571044B1 (ko)
CN (1) CN1121219C (ko)
AP (1) AP9901725A0 (ko)
AR (1) AR013131A1 (ko)
AT (1) ATE290381T1 (ko)
AU (1) AU733194B2 (ko)
BR (1) BR9810231A (ko)
CA (1) CA2295752C (ko)
DE (1) DE69829286T2 (ko)
ES (1) ES2239395T3 (ko)
HK (1) HK1029529A1 (ko)
MA (1) MA24589A1 (ko)
NO (1) NO996484L (ko)
NZ (1) NZ502062A (ko)
OA (1) OA11518A (ko)
RU (1) RU2185820C2 (ko)
SA (1) SA98190227A (ko)
TR (1) TR199903315T2 (ko)
WO (1) WO1999000131A1 (ko)
ZA (1) ZA985488B (ko)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638948B1 (en) * 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
DK0994872T3 (da) * 1997-06-10 2001-05-28 Synthon Bv 4-phenylpiperidin-forbindelser
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
US6168805B1 (en) 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
AU3810100A (en) * 1999-03-12 2000-10-04 Basf Aktiengesellschaft Stable pharmaceutical application form for paroxetin anhydrate
DE19930454A1 (de) * 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
US6503927B1 (en) * 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
EP1263413B1 (en) * 2000-03-09 2006-05-24 Ohio State University Research Foundation Method of preparing solid dispersions
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20030212105A1 (en) * 2000-12-07 2003-11-13 Agrawal Shyam Sunder Novel anti-fertility agent
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
WO2002085360A1 (en) * 2001-04-25 2002-10-31 Pentech Pharmaceuticals, Inc. Optimized procedures for the manufacture of paroxetine salts
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
HUP0400264A2 (hu) * 2001-06-22 2004-08-30 Pfizer Products Inc. Alacsony oldékonyságú és/vagy savra érzékeny hatóanyagokat és semlegesített savas polimereket tartalmazó gyógyszerkészítmények és eljárás az előállításukra
EP1412350A1 (en) * 2001-08-02 2004-04-28 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
EP1465601A4 (en) * 2001-12-28 2006-02-15 Teva Pharma STABLE PHARMACEUTICAL FORMULATION OF PAROXETINE ANHYDROUS HYDROCHLORIDE AND PREPARATION METHOD
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
KR100691608B1 (ko) * 2005-02-21 2007-03-12 (주)나노하이브리드 염기성 고분자가 첨가된 유리 염기형 약물과 층상형 규산염의 하이브리드 및 그의 제조방법
JP5153629B2 (ja) * 2005-08-02 2013-02-27 ルピン・リミテッド 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
EP1948646A2 (en) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US20080181948A1 (en) * 2006-11-15 2008-07-31 Abbott Laboratories Solid pharmaceutical dosage formulations
BRPI0720472A2 (pt) 2006-12-22 2014-01-14 Yuhan Corp Dispersão sólida contendo revaprazan e processo para a preparação da mesma
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
JP5700367B2 (ja) * 2010-05-06 2015-04-15 高田製薬株式会社 パロキセチン含有フイルムコ−テイング経口製剤
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
WO2014009970A2 (en) * 2012-07-09 2014-01-16 Hetero Research Foundation Linagliptin solid dispersion
US9381199B2 (en) 2012-07-09 2016-07-05 Hetero Research Foundation Linagliptin solid dispersion
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
US9211290B2 (en) * 2012-12-31 2015-12-15 Noven Therapeutics, Llc Solid dispersions of amorphous paroxetine mesylate
CN110114063B (zh) * 2017-01-06 2022-01-11 广东东阳光药业有限公司 鲁拉西酮固体分散体及其制备方法
RU2698400C1 (ru) * 2018-12-17 2019-08-26 Георгий Сергеевич Немов Способ лечения депрессии у собак и кошек

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721723A (en) * 1985-10-25 1988-01-26 Beecham Group P.L.C. Anti-depressant crystalline paroxetine hydrochloride hemihydrate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5147733B2 (ko) * 1974-02-15 1976-12-16
YU43349B (en) * 1983-03-16 1989-06-30 Boehringer Ingelheim Ltd Process for making a watersoluble, pharmaceutically acceptible dispersion of chlortalidone in solid state
US4933360A (en) * 1983-03-16 1990-06-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel chlorthalidone process and product
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721723A (en) * 1985-10-25 1988-01-26 Beecham Group P.L.C. Anti-depressant crystalline paroxetine hydrochloride hemihydrate

Also Published As

Publication number Publication date
ATE290381T1 (de) 2005-03-15
ZA985488B (en) 1999-04-22
AR013131A1 (es) 2000-12-13
OA11518A (en) 2004-02-04
EP0991408B1 (en) 2005-03-09
US5955475A (en) 1999-09-21
BR9810231A (pt) 2000-08-08
EP0991408A1 (en) 2000-04-12
DE69829286D1 (de) 2005-04-14
TR199903315T2 (xx) 2000-09-21
CN1265593A (zh) 2000-09-06
NO996484D0 (no) 1999-12-27
RU2185820C2 (ru) 2002-07-27
KR100571044B1 (ko) 2006-04-13
KR20010020592A (ko) 2001-03-15
CA2295752C (en) 2004-10-26
WO1999000131A1 (en) 1999-01-07
JP2002514227A (ja) 2002-05-14
CA2295752A1 (en) 1999-01-07
NZ502062A (en) 2001-10-26
MA24589A1 (fr) 1998-12-31
SA98190227A (ar) 2005-12-03
CN1121219C (zh) 2003-09-17
AU8171798A (en) 1999-01-19
HK1029529A1 (en) 2001-04-06
DE69829286T2 (de) 2006-01-12
ES2239395T3 (es) 2005-09-16
NO996484L (no) 2000-02-25
EP0991408A4 (en) 2003-07-09
AP9901725A0 (en) 1999-12-31

Similar Documents

Publication Publication Date Title
AU733194B2 (en) Novel process for manufacturing paroxetine solid dispersions
EP1075263B1 (en) Aqueous process for manufacturing paroxetine solid dispersions
TWI402082B (zh) 醫藥組合物
KR100869039B1 (ko) 나테글리니드 함유 제제
EP0274176B1 (en) Sustained release capsule or tablet formulation
JP2013209419A (ja) 酢酸バゼドキシフェン製剤
US7750165B2 (en) Metaxalone polymorphs
US20030190352A1 (en) Compositions of venlafaxine base
KR100525275B1 (ko) 시알산 유도체를 함유하는 고체분산체
KR100209201B1 (ko) 1,4-디히드로피리딘 유도체를 함유하는 고체 분산 정제 및 그의 제조방법
EP1622899B1 (en) Pioglitazone sulfate, pharmaceutical compositions and their use
MXPA00000053A (en) Novel process for manufacturing paroxetine solid dispersions
US20030022922A1 (en) Amlodipine free base
US20100178342A1 (en) Solid Pharmaceutical Preparation
EP0535269A1 (en) Pharmaceutical compositions containing thiazolidinedione derivatives
WO2005117840A1 (en) Stable pharmaceutical compositions comprising pulverized granules of nateglinide of form b

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)